Biomarin Pharmaceutical Inc. BMRN

NAS: BMRN | ISIN: US09061G1013   14/09/2026
66,41 USD (+1,11%)
(+1,11%)   14/09/2026

14 september 2026 · BioMarin Announces Appointment of Robert Plenge, M.D., Ph.D., Chief Research Officer of Bristol Myers Squibb, to Board of Directors · Persbericht

9 september 2026 · BioMarin Announces Positive Results of Phase 3 VOXZOGO® (vosoritide) Study in Hypochondroplasia Published in NEJM Evidence · Persbericht

2 september 2026 · BioMarin to Participate in Upcoming Investor Conferences · Persbericht

1 september 2026 · BioMarin Announces Close of the Alesta Therapeutics Acquisition · Persbericht

31 augustus 2026 · BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea · Persbericht

18 augustus 2026 · BioMarin to Acquire Alesta Therapeutics to Gain ALE1, a Potential First Oral Therapy for Hypophosphatasia, Adding an Important Clinical Program to BioMarin's Pipeline · Persbericht

10 augustus 2026 · BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston · Persbericht

6 augustus 2026 · BioMarin Reports Second Quarter 2026 Financial and Operating Results · Persbericht

30 juli 2026 · BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET · Persbericht

27 juli 2026 · BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome · Persbericht

13 juli 2026 · U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia · Persbericht

16 juni 2026 · BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026 · Persbericht

20 mei 2026 · BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia · Persbericht

18 mei 2026 · BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency · Persbericht

4 mei 2026 · BioMarin Reports First Quarter 2026 Financial and Operating Results · Persbericht

2 mei 2026 · BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society's 2026 Annual Meeting · Persbericht

27 april 2026 · BioMarin Completes Acquisition of Amicus Therapeutics · Persbericht

27 april 2026 · BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET · Persbericht

21 april 2026 · BioMarin Announces Board Leadership Transition · Persbericht

12 maart 2026 · BioMarin Presents New Data on the Positive Impact of Early Treatment With VOXZOGO® (vosoritide) on Proportionality and Arm Span in Children with Achondroplasia at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting · Persbericht

Mijn selecties